Ocular adverse effects of preserved vs PF medications in RCTs
| AEs | Sheddon | Day | Goldberg | |||
| PF | BAK | PF | BAK | PF | BAK | |
| Overall % | Not reported | Not reported | Not reported | Not reported | 33.1 | 33.7 |
| Conjunctival hyperaemia | Not reported | Not reported | 23.9 | 26.1 | 21.2 | 19.5 |
| Mild | Not reported | Not reported | 17.6 | 21 | 16.5 | 15.6 |
| Moderate | Not reported | Not reported | 6.3 | 4.4 | 4.0 | 3.9 |
| Severe | Not reported | Not reported | 0 | 0.7 | 0.7 | 0 |
| Pruritus | Not reported | Not reported | 4.0 | 4.1 | 4.3 | 1.8 |
| Skin pigmentation | Not reported | Not reported | Not reported | Not reported | 4 | 1.4 |
| Dry eye | Not reported | Not reported | 1.7 | 3.1 | 3.2 | 1.1 |
| Punctate keratitis | 16.8 | 23.8 | 3.0 | 3.1 | 2.9 | 2.5 |
| Eye pain | Not reported | Not reported | Not reported | Not reported | 2.5 | 1.8 |
| Foreign body sensation | Not reported | Not reported | 2.3 | 0.7 | 2.2 | 2.1 |
| Eye irritation | 16 | 21.5 | Not reported | Not reported | 2.2 | 1.8 |
| Eyelash growth | Not reported | Not reported | Not reported | Not reported | 1.4 | 2.8 |
| Erythema | Not reported | Not reported | Not reported | Not reported | 1.1 | 2.5 |
| Discontinuation due to ocular AE (by patients) | 4 | 3 | 2 | 3 | 4 | 9 |
AEs, adverse events; BAK, benzalkonium chloride; PF, preservative-free; RCT, randomised controlled trials.